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Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma
Adamantinomatous craniopharyngiomas (ACPs) are the
most common pituitary tumours in children. Although
histologically benign, these are clinically aggressive
tumours, difﬁcult to manage and associated with poor
quality of life for the patients. Several human and mouse
studies have provided unequivocal evidence that the over-
activation of the WNT/β-catenin signalling pathway
underlies the molecular aetiology of these tumours.
Recently, research using genetically modiﬁed mouse
models of human ACP have revealed a critical and unex-
pectednon-cellautonomousroleforpituitarystemcellsin
ACPtumourigenesis,whichhasexpandedthecancerstem
cell paradigm. As the result of this basic research, the
pathogenesis of ACP is being unveiled, with promising
implications for the development of novel treatments
againstthesechildhoodneoplasms.Thesebenigntumours
may additionally represent a unique model to provide
insights into the initial steps of oncogenesis.
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Introduction
Adamantinomatous craniopharyngiomas (ACPs) are
non-hormone secreting sellar tumours that mostly affect
children under 15, but can be diagnosed at any age, with
a second peak of incidence in adults between 50 and 74
years.The clinical relevance of ACP is not their associated
mortality, which is usually low when properly managed,
but their high morbidity due to serious endocrinological
disturbances and tendency to inﬁltrate locally and aggres-
sively into the hypothalamus and visual tracts. Currently,
there are no speciﬁc treatments against these tumours,
only surgery and/or radiotherapy, but these are not cura-
tive and patients often experience tumour recurrence.
Consequences of the tumour and its treatment are long
lasting and associated with poor quality of life for the
survivors, making many clinicians consider human ACP
as a chronic disease [1,2].
This review aims to discuss the pathogenesis of human
craniopharyngioma from an embryological perspective,
arguing that the majority of human ACPs are develop-
mental tumours. It will present results obtained from
human and mouse studies, highlighting the implications
of data derived from current research using validated
mouse models for these human neoplasms. In particular,
it will provide an overview on the critical ﬁndings that
have helped delineate the early cellular and molecular
mechanisms resulting in development of ACP, with a par-
ticular emphasis on the role of pituitary stem cells. For
in-depth analysis of the clinical aspects of human ACP,
such as treatments and patient management, readers are
directed to the other reviews on these topics [1,3–12].
Pathology of human ACP
Human ACPs are cystic tumours located either within or
above the sellar region, frequently compromising the
hypothalamus, pituitary gland, pituitary stalk and optic
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Neuropathology and Applied Neurobiology (2015) doi: 10.1111/nan.12226chiasm. The histopathology of these tumours is charac-
terized by the formation of a peripheral basal cell layer of
palisading epithelium, loose aggregates of epithelial stel-
late cells, nodules of anucleated ghost cells with brightly
eosinophilic cytoplasm termed wet keratin, large areas of
regressive changes, that is, hemosiderin deposits, choles-
terol clefts, multinucleated foreign-body giant cells,
inﬂammation and calciﬁcations [13–16].
A histopathological hallmark of human ACP is the
presence of cells showing nucleo-cytoplasmic accumula-
tion of β-catenin, which often gather to form whorl-like
structures close to the invasive front (hereby referred to as
‘cell clusters’) [9,17–20] (Figure 1). These are clearly a
minority of cells and are distributed evenly throughout
the tumour. These β-catenin-accumulating cluster cells
show activation of the WNT/β-catenin pathway as evi-
denced by the expression of pathway targets such as
AXIN2, LEF1 and BMP4 [18,21,22]. They distinctly
express stem cell markers [23] and the tight junction
protein Claudin-1 [24].The presence of these clusters is a
hallmark that differentiates human ACP from any other
tumourof thesellarregion,includingthepapillarytypeof
craniopharyngioma [25].
The cell of origin of human ACP remains unknown.
The pattern of expression of cytokeratins is consistent
with oral epithelial origin, and it is generally believed that
these neoplasms derive from remnants of Rathke’s pouch,
the embryological primordium of the anterior pituitary
[26,27].
WNT/β-catenin signalling is required for
normal development of the pituitary gland
Thepituitaryglandisamasterendocrineorganthatregu-
lates essential physiological processes including growth,
reproduction, metabolism and stress response. The
mature gland, consisting of the anterior and posterior
pituitary (AP and PP, respectively), starts to develop
around 9.0 days post coitum (dpc) in mice and around
week 4 in humans from two distinct germ layers
(Figure 2). The AP derives from Rathke’s pouch, a region
of the oral epithelium of the early embryo that contains
the undifferentiated precursors of all of the hormone-
producing endocrine cells of the mature pituitary as well
as tissue-speciﬁc pituitary stem cells of the adult organ
[28]. The PP is of neural origin and originates from a
diverticulum at the ﬂoor of the prospective hypothalamus
called the infundibulum. The PP is hypocellular and con-
tains the axons of the oxytocin and arginine vasopressin
neurons of the hypothalamus.The PP is connected to the
hypothalamus through the pituitary stalk, which com-
prises the portal vessels and hypothalamic axons.
Normal morphogenesis and differentiation of the pitui-
tary gland are regulated by the activity of several tran-
scriptional factors and signalling pathways [29–31]. One
of these pathways is WNT/β-catenin, a major regulator
of several cellular processes during organogenesis and
adulthood [32,33]. The activity of the WNT/β-catenin
pathway is controlled by the stability of β-catenin, a tran-
scriptional activator lacking a DNA binding domain. In
the absence of WNT ligands, β-catenin is phosphorylated
by a destruction complex and degraded rapidly, via the
ubiquitination pathway, preventing its stabilization and
the activation of the pathway. Binding of WNT ligands to
their receptors disrupts the destruction complex, prevent-
ing the phosphorylation of β-catenin and its subsequent
ubiquitination and degradation. Stabilized β-catenin can
translocate into the nucleus and interact with DNA-
bindingtranscriptionfactorsof theTCF/LEFfamilytoacti-
vate the expression of target genes of the pathway
(Figure 3).
Genetic studies in mice have demonstrated the require-
ment of this pathway for normal pituitary morphogenesis
anddifferentiation.WNT/β-cateninisnecessaryfortermi-
nal differentiation of hormone-producing cells at late
stages of pituitary development, while it must be inhibited
atearlystagestoestablishnormalproliferationof Rathke’s
pouch progenitors [34–39]. Supporting this notion, the
up-regulation of the WNT/β-catenin pathway in Rathke’s
pouch (RP) progenitors leads to dramatic pituitary hyper-
plasia,ectopicpituitarytissueintheoropharyngealcavity
and perinatal death in 80% of pups. In addition,
somatotroph, lactotroph and thyrotroph differentiation is
impaired[21].Thisgeneticallymodiﬁedmousemodelhar-
boursamutatedformof β-cateninthatistranscriptionally
active, but lacks the amino acids encoded by exon 3 of
Ctnnb1 (the gene encoding β-catenin), preventing its
phosphorylationandsubsequentdegradation,andleading
totheover-activationof theWNT/β-cateninpathway[40].
Over-activation of the WNT/β-catenin pathway
underlies the molecular aetiology of human
and mouse ACP
An interesting observation of the previously described
embryonic mouse line (hereby referred to as the
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© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological SocietyFigure 1. Histomorphological features of mouse and human ACP. (A) Haematoxylin and eosin staining of mouse and human tumours
showing the presence of microcystic changes (stellate reticulum; arrows) and whorl-like nodular structures (cell clusters; arrowheads). (B)
Immunohistochemistry with a speciﬁc anti-β-catenin antibody showing the presence of cell clusters with nucleo-cytoplasmic accumulation
of β-catenin. Reproduced with permission from PNAS (Gaston-Massuet et al., PNAS USA 2011, vol. 108, number 28, pp 11482–11487).
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on behalf of British Neuropathological SocietyFigure 2. Cartoon showing mouse pituitary development from 9.5 to 18. 5 dpc. Rathke’s pouch (RP) forms at 9.5 dpc as an evagination of
the oral ectoderm (OE) at the boundary between OE and pharyngeal endoderm (PE). The epithelium of RP contains the undifferentiated
progenitors that give rise to all hormone-producing cells at the end of gestation. By 11.5 dpc, RP pinches off from the oral ectoderm and
establishes contacts with the infundibulum (INF), a recess of the ﬂoor of the diencephalon (DI). RP progenitors proliferate rapidly from
9.5 dpc and the progeny migrates ventrally and initiates differentiation to populate the primordium of the anterior lobe (AL) of the pituitary.
The presumptive intermediate lobe (IL) is indicated. At 18.5 dpc, just prior to birth, the pituitary comprises the posterior lobe (PP), of neural
origin, and the anterior pituitary (AP), derived from the anterior and intermediate lobes. The pituitary is located between the hypothalamus
(Hyp) and the basosphenoid bone (BS). (Figure courtesy of Dr C. L. Andoniadou.)
Figure 3. WNT/β-catenin signalling pathway. (A) In the absence of WNT ligands, β-catenin is trapped in a destruction complex formed by
Axin, APC and GSK3β and phosphorylated in speciﬁc residues encoded by exon 3 of CTNNB1. This results in rapid degradation of β-catenin
and, consequentially, the repression of target genes brought about by the interaction of TCF/LEF1 with co-repressors [e.g. groucho
(Gro)/TLE family members]. (B) Binding of WNT ligands to the Frizzled (FZD) receptors and ist co-receptors LRP leads to the activation of
dishevelled (DVL) and recruitment to the cytoplasmic membrane of both DVL and Axin. This causes the dysruption of the destruction
complex, releasing β-catenin, which cannot be efﬁciently phosphorylated or degraded. The stabilisation of β-catenin results in increased
cytoplasmic protein levels and eventually nuclear translocation, where its interaction with TCF/LEF1 factors mediates the expression of
target genes oft he pathway. (C) Expression of a stable form of β-catenin lacking the amino acids encoded by exon 3 of CTNNB1 (small red
circle in BCAT) results in protein stabilisation as mutant β-catenin cannot be properly phosphorylated or degraded. This causes the
activation of the WNT/β-catenin pathway in a cell-autonomous manner in the absence of WNT ligands. (Figure courtesy of Dr C. L.
Andoniadou.)
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on behalf of British Neuropathological Society‘embryonic ACP model’) is that the remaining 20% of the
pups survive weaning but show variable growth defects
and fully penetrant pituitary tumours, with a median sur-
vival of around 11 weeks of age [21]. Histopathological
analyseshaverevealedcharacteristichallmarksof human
ACP such as large cysts, cell clusters with nucleo-
cytoplasmic accumulation of β-catenin and expression of
Axin2, Lef1 and Bmp4, indicating the activation of the
Wnt/β-catenin pathway [21,25,41]. These neoplastic
cells do not express markers of proliferation or pituitary
hormonesandarenegativeforsynaptophysin,amarkerof
neurons and endocrine cells (Figure 4 and data not
shown) [21,42,43]. Therefore, cluster cells in mouse and
human ACPs have exited the cell cycle, are undifferenti-
ated and possibly not of either neural or endocrine origin.
However, contrary to the human counterpart, mouse
ACPs do not show wet keratin or calciﬁcation, suggesting
species-speciﬁc differences between mouse and human
ACPs. Critically, human ACPs develop over years, but
mouse ACPs develop in a period of weeks. Despite these
differences, the mouse tumours are more similar to
human ACP than to any other tumour of the sellar region
includingpituitaryadenoma,Rathke’scleftcystsandeven
the papillary type of craniopharyngioma.
MutationsinCTNNB1havebeenidentiﬁedinmostof the
human ACP samples analysed [17,19,20,44–46]. These
aremostlyrestrictedtoexon3andresultinthesubstitution
or deletion of the critical regulatory amino acids that
control stabilization of the protein, predicted to lead to its
nucleocytoplasmic accumulation and over-activation of
the WNT/β-catenin pathway [21,22,25,41,47]. Human
mutations are functionally equivalent to the mutated
β-catenin expressed in the embryonic ACP model.
Together, the human and mouse studies have provided
robust evidence for a role of CTNNB1 mutations and the
over-activation of the WNT/β-catenin pathway in the
molecular aetiology of ACP.
Childhood-onset ACP is likely to be a tumour
of embryonic origin
Further molecular and genetic studies using the embry-
onic ACP mouse model have revealed two interesting ﬁnd-
ings on the pathogenesis of human ACPs, in particular, of
childhood-onset ACP. First, genetic approaches in mice
have demonstrated that tumours form only when onco-
genicβ-cateninisexpressedinRathke’spouchundifferen-
tiated precursors, but not when committed progenitors or
fully differentiated hormone-producing cells are targeted.
Second, analyses of mouse embryos at different stages of
development have revealed that β-catenin-accumulating
cell clusters with a similar gene expression proﬁle to the
human clusters are present in the pituitary gland of the
embryonic ACP model by the end of gestation [21].
Are these conclusions applicable to the human
tumours?The similarities between the mouse and human
clustersareremarkable,notonlymorphologicallybutalso
atthemolecularlevel,stronglysuggestingthattheyrepre-
sent equivalent structures in mouse and human ACPs. In
fact, whole transcriptome gene expression proﬁling of the
mouse cluster cells has revealed numerous genes/
pathways that are dysregulated in the mouse and also in
thehumantumours[42].ThepossibilitythatACPpatients
mayhavecellclustersinthepituitaryglandissupportedby
clinicalevidence.Inaretrospectiveanalysisof 90children
diagnosed with ACP (median age at diagnosis 8.3 years),
Mullerandcolleagueshavereportedasigniﬁcantdecrease
inheightscoreat10–12monthsof agethatpersisteduntil
the diagnosis of ACP [48]. Of note, somatotrophs are
clearlydefectiveintheembryonicACPmodelbytheendof
gestation and postnatally resulting in dwarﬁsm [21].
Therefore, it is tempting to suggest that clusters may
develop embryologically in human patients and may be
present in the pituitary gland of the newborn prior to the
appearance of any tumour mass. In fact, foetal ACP was
recently diagnosed in a 18 week human foetus [49].
Pituitary stem cells play a critical role in the
pathogenesis of ACP
The presence of tissue-speciﬁc stem cells has been demon-
strated in several organs including the brain, gastrointes-
tinal tract, skin, bone marrow and skeletal muscle among
others.These cells can self-renew, express markers associ-
atedwithstemness(e.g.Sox2)andcangiverisetoprogeny
able to differentiate and contribute to tissue homeostasis
as well as regeneration [32,50]. The existence of similar
cells in the adult murine pituitary gland has been long
suspected [51], but not fully demonstrated until recently,
by using genetic tracing in the mouse [52,53]. Pituitary
stem cells express the transcription factors SOX2 and
SOX9 and are capable of differentiating into all of the
hormone-producing cells to contribute to organ homeo-
stasis and regeneration. In the adult human pituitary,
SOX2+ve cells have also been identiﬁed, suggesting that
stem cells may also exist in the human organ [54].
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on behalf of British Neuropathological SocietyFigure 4. Cluster cells in mouse and human ACP do not express Ki67 or SOX9. Double immunoﬂuorescent staining against β-catenin
(green) and the proliferative marker Ki67 or the transcription factor SOX9 (red). Reproduced with permission from PNAS (Gaston-Massuet
et al., PNAS USA 2011, vol. 108, number 28, pp 11482–11487).
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on behalf of British Neuropathological SocietyTissue-speciﬁc stem cells can be the origin of cancer, a
concept that has fuelled the cancer stem cell (CSC) para-
digm. This proposes that within tumours and cancers,
there is a minority of transformed cells capable of self-
renewing and generate the progeny that populate the
tumour bulk. As CSCs may be particularly resistant to
chemotherapy and radiation, it is thought that they can
be responsible for cancer evolution, recurrence and
metastasis, raising a signiﬁcant interest in the oncology
ﬁeld as potential targets for novel speciﬁc therapies
[55–60].
The presence of CSCs in pituitary tumours, and speciﬁ-
cally in human ACP, has recently been investigated using
genetic approaches. A mouse model was generated by
activating the WNT/β-catenin pathway exclusively in
SOX2+ve adult pituitary stem cells [52]. These mice,
referredtoasthe‘adultACPmodel’,alsodeveloppituitary
tumours that are composed of synaptophysin-negative
and undifferentiated (i.e. neither endocrine nor neural)
tumour cells. Importantly, these tumours contain β-
catenin-accumulating cell clusters, indicating a signiﬁ-
cant resemblance to both human ACP and the embryonic
modelpreviouslydescribed.Takingintoconsiderationthis
mouse research, it could be speculated that mutations in
CTNNB1 in SOX2+ve stem cells of the mature adult pitui-
tary are the cause of adulthood-onset ACP in humans,
while the same mutations in undifferentiated RP progeni-
tors may lead to childhood-onset ACP. Further molecular
characterization of adult and childhood ACP may help
resolve this hypothesis.
It was important to address whether the mutated
SOX2+ve cells in the adult ACP model were CSCs. To
address this important question, SOX2+ve stem cells have
been targeted to simultaneously express oncogenic
mutant β-catenin and yellow ﬂuorescent protein (YFP). If
normal SOX2+ve cells were transformed into CSCs due to
the expression of oncogenic β-catenin, the tumour would
be expected to contain YFP+ progeny cells. Surprisingly,
tumours do not express YFP, indicating that the cell of
origin of mouse ACP is not a targeted SOX2+ve cell
(Figure 5) [52]. The targeted SOX2+ve cells proliferate
transiently due to the over-activation of the WNT/β-
catenin pathway; but soon after this burst of cell division,
they exit the cell cycle and form cell clusters with nucleo-
cytoplasmic accumulation of β-catenin, like those
observed in human ACP. Two conclusions can be drawn
from these studies: (i) SOX2+ve stem cells are not the cell
of origin of ACP; however, they are the origin of the
typical cell clusters that characterize these neoplasms; (ii)
mutated SOX2+ve cells expressing oncogenic β-catenin
are not CSCs according to the classical deﬁnition of the
CSCparadigm,sincetheirdescendantsdonotcolonizethe
tumours, rather they induced tumours in a non-cell
autonomous manner.
Figure 5. The progeny of SOX2
+ pituitary stem cells give rise to the cell clusters but are not the cell-of-origin of mouse ACP. Double
immunoﬂuorescence staining reveals the presence of a β-catenin-accumulating tumour (asterisk) that is YFP−ve. Note that YFP−ve tumour is
adjacent to YFP+ve cell clusters showing nucleo-cytoplasmic β-catenin accumulation (arrowheads). Reproduced with permission from
Elsevier (Andoniadou et al., Cell Stem Cell 2013, vol. 13, issue 4, pp 433–445).
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pituitary stem cells in tumourigenesis
If murine ACP tumours are not derived from the mutated
SOX2+ve stem cells in a cell-autonomous manner, what is
the mechanism underlying tumour formation? Molecular
analyses have provided some interesting and provocative
insights into this question. Using genetic approaches, the
cluster cells have been isolated from the embryonic mouse
model and their gene expression proﬁled in comparison
with the non-cluster tumour cells to identify dysregulated
genes/pathways [42]. The studies have revealed that
cluster cells function like signalling centres by expressing
a great variety of secreted proteins including members of
the ﬁbroblast growth factor (FGF), transforming growth
factor beta (TGFβ), epithelial growth factor (EGF) and
sonic hedgehog (SHH) pathways. In addition, several
chemokines and cytokines as well as their receptors,
which are critical mediators of inﬂammation, are also
up-regulated in the mouse clusters. Of interest, proteins
with pro-inﬂammatory properties have been identiﬁed in
thecysticﬂuidof humanACP,suggestingthatACPmaybe
an inﬂammation-driven tumour [13–16]. Many of these
factors have been shown to be expressed in several
tumours/cancers and play critical roles in tumour biology
[61–65].
Normal embryogenesis relies heavily on signalling
centres. Broadly speaking, normal organogenesis includ-
ingpituitarymorphogenesisisbroughtaboutbytheactivi-
ties of cells with instructive properties that secrete signals
(i.e. signalling centres) and those of surrounding cells,
which respond to those signals. In mouse ACP, β-catenin-
accumulating cell clusters secrete factors affecting the
tissue microenvironment in a paracrine manner, pro-
moting cell transformation and tumourigenesis. In this
paracrine model of involvement of stem cells in
tumourigenesis, the cell sustaining the oncogenic muta-
tionandthecellof originof thetumoursaredifferent[52]
(Figure 6).
An important question is to what extent these ﬁndings
are relevant to human ACP. Several lines of evidence
support the view that the pathogenesis of mouse and
human ACP are very similar: (i) recent research using a
xenograft model of human ACP in immunosuppressed
mice has shown that the activities of the clusters are criti-
cal to regulate cell behaviour in the invasive front of the
tumours [66]; (ii) human clusters also express FGFs,
TGFβs, SHH, chemokine receptors and other secreted
factors capable of modifying the tumour microenviron-
ment and promoting tumour growth [22,42,67,68]; (iii)
cluster cells in the human tumours are non-proliferative,
undifferentiated (i.e. neither endocrine not neural) and
Figure 6. Paracrine model of involvement of pituitary stem cells in tumourigenesis. When targeted to express oncogenic β-catenin, SOX2+ve
cells (green) accumulate nucleo-cytoplasmic β-catenin, proliferate transiently and stop dividing forming clusters. Clusters secrete signals to
the surrounding cells to induce cell transformation and tumour growth from a cell that is not derived from the targeted SOX2
+ve stem cell.
Reproduced with permission from Elsevier (Andoniadou et al., Cell Stem Cell 2013, vol. 13, issue 4, pp 433–445).
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clustersarepresentinthemajorityof humanACP,evenin
very large and advanced tumours, suggesting that their
activities must be required for growth and/or survival of
tumourcells.If thiswasnotthecase,itwouldbedifﬁcultto
explain why the tumour ends up killing all of the normal
pituitary tissue, but sparing a limited population of non-
dividing cells forming clusters. Whether the paracrine
signals of the clusters may also be required for the initial
transformation of the cell of origin of the tumour is an
importantquestionthatrequiresfurtherresearch.Moreo-
ver,itispossiblethattheparacrinemodelmaybeapplicable
to other pituitary tumours and human cancers as pub-
lished evidence suggests its broader implications in the
oncology ﬁeld [69–74].
Conclusions and open questions
The pathogenesis of human ACP is being revealed and
several dysregulated genes and pathways have been iden-
tiﬁed, which may impact the diagnosis, prognosis and
treatmentof patientsintheyearstocome.Itisestablished
thatmutationsinCTNNB1resultingintheover-activation
of the WNT/β-catenin pathway underlie the aetiology of
ACP, but many questions remain unanswered. Why are
the tumourigenic effects of mutant β-catenin restricted
only to Rathke’s pouch embryonic precursors and adult
pituitary stem cells? Research from mouse models has
demonstrated that only these undifferentiated cells are
able to induce tumours when targeted with oncogenicβ-
catenin. This is likely to be the case in human ACP, when
taking into account the similarities in the pathogenesis
and the possibility that childhood-onset ACP is likely to be
a developmental tumour.
Which is the cell of origin of the tumours? It is puzzling
thatmutatedSOX2+vestemcellsintheadultpituitaryare
not the cell of origin of the tumours in the mouse as it
wouldbeexpectedaccordingtotheCSCparadigm.Instead
they induce tumours in a non-cell autonomous manner
by activating a secretory phenotype with tumour-
inducing potential. Whether cluster cells may or may be
not the origin of human ACP requires detailed molecular
analyses. Of note, Holsken et al. (2009) revealed the pres-
ence of different CTNNB1 mutations inside and outside
the clusters in 50% of the human ACP analysed, suggest-
ing the existence of tumour heterogeneity as described in
mouse ACP [22].
Which are the dysregulated pathways in human ACP?
Mouse and human studies have discovered several path-
ways that are dysregulated in ACP, but non-biased large-
scale gene expression analyses of human ACP are needed
to identify other targetable pathways and novel
biomarkers capable of predicting tumour behaviour such
as inﬁltrative potential and recurrence.
Could the study of these benign tumours provide novel
insights into the origin of cancer? If cancer is considered
as the malignant progression of a pre-malignant lesion,
then benign tumours offer a window of opportunity to
better understand the early steps of cell transformation
and tumour initiation. Such knowledge is needed if we
aim to improve early diagnosis and to develop treatments,
which eliminate tumour cells at more vulnerable stages of
cancer progression. The paracrine mechanism described
using the adult ACP model has broadened our knowledge
on how adult stem cells contribute to tumourigenesis
beyond the classical CSC paradigm. Future research is
required to dissect this model further and to assess its
impact in the cancer ﬁeld.
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